Low frequency of intermittent HIV-1 semen excretion in patients treated with darunavir-ritonavir at 600/100 milligrams twice a day plus two nucleoside reverse transcriptase inhibitors or monotherapy

Antimicrob Agents Chemother. 2010 Nov;54(11):4910-3. doi: 10.1128/AAC.00725-10. Epub 2010 Aug 16.

Abstract

HIV-1 RNA level and darunavir concentration in the genital tract were measured in 45 men receiving darunavir-ritonavir mono- or tritherapy. At week 48, a low frequency (3/45) of HIV-1 RNA shedding was observed in patients (1 on monotherapy and 2 on triple therapy), although they had undetectable HIV-1 RNA in plasma. The median darunavir seminal plasma concentration was close to the blood plasma free fraction, demonstrating a good penetration of darunavir into the male genital tract.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Darunavir
  • Drug Administration Schedule
  • HIV Infections / blood
  • HIV Infections / drug therapy
  • HIV Infections / metabolism
  • HIV-1 / drug effects
  • HIV-1 / pathogenicity
  • Humans
  • Male
  • Plasma / chemistry
  • RNA, Viral / genetics
  • Reverse Transcriptase Inhibitors / blood
  • Reverse Transcriptase Inhibitors / metabolism
  • Reverse Transcriptase Inhibitors / therapeutic use*
  • Ritonavir / blood
  • Ritonavir / metabolism
  • Ritonavir / therapeutic use*
  • Semen / chemistry
  • Sulfonamides / blood
  • Sulfonamides / metabolism
  • Sulfonamides / therapeutic use*

Substances

  • RNA, Viral
  • Reverse Transcriptase Inhibitors
  • Sulfonamides
  • Ritonavir
  • Darunavir